Latest revenue
—
as of 2025-04-30
Latest net income
$-4.5M
as of 2025-04-30
Net margin
—
as of 2025-04-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ALZN is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $4.3M
- Enterprise value
- $1.8M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.95×
- Dividend yield
- 0.0%
- 52-wk high
- $3.64
- 52-wk low
- $0.85
- Beta
- —
- Shares out
- 3.8M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
About ALZN
Business description and risk factors will appear here once ALZN's latest filing is fully ingested.
Profitability
Return on equity
-113.8%
129.7%Return on assets
-98.1%
93.8%Leverage
Debt / equity
0.16×
112.9%Debt / assets
13.8%
97.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-01-31 | — | — | $-2.2M | -111.6% | — |
Q4 2025 2025-10-31 | — | — | $-1.0M | +26.5% | — |
Q3 2025 2025-07-31 | — | — | $-2.7M | -177.4% | — |
Q2 2025 2025-04-30 | — | — | $-1.1M | -33.8% | — |
Q1 2025 2025-01-31 | — | — | $-1.0M | +61.0% | — |
Q4 2024 2024-10-31 | — | — | $-1.4M | +53.1% | — |
Q3 2024 2024-07-31 | — | — | $-974.4K | +72.4% | — |
Q2 2024 2024-04-30 | — | — | $-851.5K | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ALZN — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$108.9K
Insider selling
$2.2M
Net activity
−$2.1M
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ALZN
Institutional value
$48.4K
Total shares held
45.6K
Distinct holders
9
-3 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD FIDUCIARY TRUST CO | 21.0K | $22.3K | — | New |
| 2 | Clearstead Advisors, LLC | 10.0K | $10.6K | +0 (+0.0%) | No change |
| 3 | CITIGROUP INC | 5.2K | $5.5K | — | New |
| 4 | UBS Group AG | 4.5K | $4.8K | -20.1K (-81.7%) | Trimmed |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4.4K | $4.7K | — | New |
| 6 | BlackRock, Inc. | 437 | $463 | +0 (+0.0%) | No change |
| 7 | SBI Securities Co., Ltd. | 22 | $23 | +0 (+0.0%) | No change |
| 8 | Caitong International Asset Management Co., Ltd | 4 | $4 | — | New |
| 9 | HARBOR INVESTMENT ADVISORY, LLC | 1 | $1 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ALZN's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.